HER2-positive Clinical Trials in Beijing, Beijing Municipality
18 recruitingBeijing, Beijing Municipality, China
Showing 1–18 of 18 trials
Recruiting
Phase 3
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
HER2-positive Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.416 enrolled75 locationsNCT07047365
Recruiting
Early Phase 1
SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
HER2-Positive Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd150 enrolled17 locationsNCT05245058
Recruiting
Phase 1Phase 2
A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors
Her2-positive/Low-expression Urinary and Digestive Tract Tumors
Sichuan Baili Pharmaceutical Co., Ltd.42 enrolled1 locationNCT06031584
Recruiting
Phase 3
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.544 enrolled78 locationsNCT07043725
Recruiting
Phase 3
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
HER2-positive Breast Cancer
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.540 enrolled1 locationNCT07377643
Recruiting
Phase 1Phase 2
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
HER2-positive Advanced Solid Tumor
DualityBio Inc.796 enrolled102 locationsNCT05150691
Recruiting
Phase 2Phase 3
The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study
HER2-positive Breast CancerPyrotinib Treatment
Cancer Institute and Hospital, Chinese Academy of Medical Sciences964 enrolled1 locationNCT06958627
Recruiting
Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients
HER2-positive Breast Cancer
Shu Wang171 enrolled1 locationNCT06722599
Recruiting
Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
HER2-positive Breast Cancer
Shu Wang2,916 enrolled1 locationNCT06722612
Recruiting
Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer
HER2-positive Breast Cancer
Shu Wang285 enrolled1 locationNCT06711055
Recruiting
Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
HER2-positive Breast Cancer
Shu Wang8,077 enrolled1 locationNCT06711068
Recruiting
De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients
HER2-positive Breast Cancer
Shu Wang519 enrolled1 locationNCT06700369
Recruiting
Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
HER2-positive Breast Cancer
Shu Wang2,806 enrolled1 locationNCT06693024
Recruiting
Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
HER2-positive Breast Cancer
Shu Wang2,092 enrolled1 locationNCT06693037
Recruiting
Phase 2
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
HER2-positive Locally Advanced Resectable Gastric Cancer
Peking University18 enrolled1 locationNCT06023758
Recruiting
Phase 1Phase 2
HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors
HER2-Positive Advanced Solid Tumors
Chinese PLA General Hospital30 enrolled1 locationNCT05681650
Recruiting
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer
HER2-positive Breast CancerEarly Stage Breast Cancer
Peking Union Medical College Hospital300 enrolled1 locationNCT06035016
Recruiting
Phase 2
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
HER2-positive Breast Cancer
Peking University104 enrolled1 locationNCT04481932